Improved Nutrition for Cystic Fibrosis and Pancreatic Insufficiency Patients Patent for BIO-CAT
The U.S. Patent and Trademark Office has granted Troy, Virginia-based BIO-CAT a patent for the use of a microbial enzyme system, including a lipase enzyme, to improve digestion for patients suffering from pancreatic insufficiency, including cystic fibrosis patients.
“Digestion of foods in normal diets is a challenge for these types of patients due to many complicating factors associated with the diseases. Our innovation is focused on providing a blend of enzymes that would help breakdown or digest materials normally found in every day foods – namely carbohydrates, lipids and protein. Additionally, our technology offers the patient an alternative to animal derived enzymes currently prescribed to address digestion issues for these patients,” said BIO-Cat’s CEO Ed Schuler.
The innovation to use this enzyme blend arose from many years of studying the effect of microbial enzymes in improving digestion, through enzyme supplementation in normal individuals. BIO-CAT has long been a supplier to the dietary supplement industry and has built upon these experiences to develop unique technical positions to evaluate use of safe, microbial enzymes in order to help address these types of dietary issues and ailments.
BIO-CAT will be conducting further clinical studies to optimize the technologies in order to bring the product to market.
